Short Interest in Aclarion, Inc. (NASDAQ:ACON) Drops By 6.0%

Aclarion, Inc. (NASDAQ:ACON) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 279,800 shares, a decrease of 6.0% from the August 31st total of 297,700 shares. Based on an average daily volume of 575,200 shares, the days-to-cover ratio is presently 0.5 days. Currently, 3.0% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets reiterated a “buy” rating and issued a $1.50 target price (down previously from $1.60) on shares of Aclarion in a report on Monday, August 26th.

Aclarion Price Performance

ACON opened at $0.18 on Wednesday. The business has a fifty day moving average price of $0.23 and a 200 day moving average price of $0.28. Aclarion has a 12 month low of $0.16 and a 12 month high of $9.90.

Aclarion (NASDAQ:ACON) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.04. Aclarion had a negative net margin of 10,967.15% and a negative return on equity of 910.84%. The business had revenue of $0.01 million during the quarter. Research analysts anticipate that Aclarion will post -0.99 EPS for the current year.

Institutional Trading of Aclarion

A hedge fund recently bought a new stake in Aclarion stock. Virtu Financial LLC bought a new position in shares of Aclarion, Inc. (NASDAQ:ACON) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 1.40% of Aclarion as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 7.52% of the company’s stock.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.